Trending Stock News

Analysts See $0.20 EPS for Northfield Bancorp, Inc. (Staten Island, NY); Last Week Five Prime Therapeutics, Inc. (FPRX) Analysts

Analysts expect Northfield Bancorp, Inc. (NASDAQ:Staten Island, NY) to report $0.20 EPS on April, 25 after the close.They anticipate $0.05 EPS change or 33.33% from last quarter’s $0.15 EPS. NFBK’s profit would be $9.83M giving it 19.71 P/E if the $0.20 EPS is correct. After having $0.19 EPS previously, Northfield Bancorp, Inc.’s analysts see 5.26% EPS growth. The stock increased 0.51% or $0.08 during the last trading session, reaching $15.77. About 51,493 shares traded. Northfield Bancorp, Inc. (NASDAQ:Staten Island, NY) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 11 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Five Prime Therapeutics had 25 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Buy” on Monday, November 6. BMO Capital Markets maintained Five Prime Therapeutics, Inc. (NASDAQ:FPRX) rating on Wednesday, September 20. BMO Capital Markets has “Hold” rating and $39.0 target. The firm has “Buy” rating by Jefferies given on Wednesday, June 7. The company was maintained on Monday, October 19 by Oppenheimer. The company was upgraded on Tuesday, August 11 by Zacks. BMO Capital Markets upgraded the stock to “Outperform” rating in Monday, October 16 report. Credit Suisse initiated the stock with “Outperform” rating in Thursday, January 21 report. The stock of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has “Buy” rating given on Thursday, March 1 by Jefferies. The stock has “Market Perform” rating by BMO Capital Markets on Tuesday, April 12. The stock has “Buy” rating by Jefferies on Monday, September 11. See Five Prime Therapeutics, Inc. (NASDAQ:FPRX) latest ratings:

01/03/2018 Broker: Jefferies Rating: Buy New Target: $40.0 Maintain
28/02/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $75 New Target: $60 Maintain
28/02/2018 Broker: Nomura Old Rating: Buy New Rating: Buy Old Target: $94 New Target: $25 Maintain
15/02/2018 Broker: Guggenheim Rating: Buy New Target: $30.0 Maintain
07/11/2017 Broker: Leerink Swann Rating: Buy
07/11/2017 Broker: Nomura Rating: Buy
07/11/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $71 New Target: $75 Maintain
06/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $50.0 Maintain

Investors sentiment increased to 1.34 in Q4 2017. Its up 0.30, from 1.04 in 2017Q3. It increased, as 21 investors sold Five Prime Therapeutics, Inc. shares while 29 reduced holdings. 24 funds opened positions while 43 raised stakes. 25.47 million shares or 6.30% more from 23.96 million shares in 2017Q3 were reported. State Of Wisconsin Investment Board has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). State Bank Of New York Mellon Corporation reported 150,245 shares. Rock Springs Capital Mgmt L P has invested 0.42% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Virginia Retirement Et Al owns 23,200 shares or 0.01% of their US portfolio. Deutsche Fincl Bank Ag reported 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). National Bank & Trust Of Montreal Can invested in 405 shares. Moreover, Voya Inv Lc has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Fifth Third Comml Bank stated it has 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Moreover, Quantbot Techs L P has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 1,592 shares. Cubist Systematic Strategies holds 0.01% or 9,808 shares in its portfolio. Clarivest Asset Mgmt Ltd Llc reported 0.01% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). 132,865 were accumulated by Axa. 1,753 were accumulated by Zurcher Kantonalbank (Zurich Cantonalbank). Fmr Lc has invested 0.01% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Dimensional Fund Advsr Limited Partnership holds 0.01% or 974,276 shares.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $599.08 million. The companyÂ’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

The stock decreased 0.23% or $0.04 during the last trading session, reaching $17.06. About 310,323 shares traded. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 52.34% since April 17, 2017 and is downtrending. It has underperformed by 63.89% the S&P500.

Northfield Bancorp, Inc. (NASDAQ:Staten Island, NY) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *